Novomedix is a biotechnology company that is dedicated to transforming the treatment of cancer and fibrosis. With their expertise in drug development and a focus on small molecule multi-pathway modulators, Novomedix is making significant strides in the field. Their therapies target key pathways of cancer, fibrosis, and lung disease, addressing the hallmarks of these conditions.

Their pipeline includes a library of oral small molecule IL-11 inhibitors, which have shown promising results in animal models of cancer and fibrosis. One of their lead candidates, NMX1, not only treats tumors by inhibiting mTOR signaling and IL-11 secretion but also protects the heart by activating AMPK. Novomedix is also actively working on developing therapies for fibrotic diseases, liquid tumors, and atopic dermatitis.

With a commitment to improving patients' lives, Novomedix is pushing the boundaries of innovation in the field of cancer and fibrosis drug development